Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

REVIVE Zug: Impact of a Cantonal First Repsonder System on ROSC Rates and Incidence of Shockable Rhythms in Out-of-hospital Cardiac Arrest

NCT07323667 is registered in ClinicalTrials.gov with Felix Brinkmann as lead sponsor.

NCT NCT07323667
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07323667 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
REVIVE Zug: Impact of a Cantonal First Repsonder System on ROSC Rates and Incidence of Shockable Rhythms in Out-of-hospital Cardiac Arrest
Lead sponsor
Felix Brinkmann
Phase
Observational
Overall status
Enrolling by invitation
Start date
July 25, 2025
Completion date
August 31, 2027
Enrollment
250 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

bystander effect, cardiac arrest (ca), cardiac arrest with successful resuscitation, cardiopulmonary resuscitation (cpr), critical care medicine, defibrillators, emergency medical services, first aid, paramedical professionals, resuscitation, survival rate